Profile data is unavailable for this security.
About the company
Ipsen SA is a France-based biopharmaceutical group specialized in specialty care. The Company operates globally through two segments: Specialty Care and Consumer Healthcare. In Specialty Care, the Company is focused on various therapeutic areas, including oncology, neurosciences and rare diseases. Its oncology portfolio includes Somatuline, Decapeptyl, Cabometyx and Onivyde. Its neuroscience portfolio includes Dysport, and in rare diseases key products are NutropinAq and Increlex. Its primary care portfolio includes Smecta, Forlax, Fortrans, Eziclen, and Tanakan. In oncology Ipsen focuses on a number of disease areas, which include neuroendocrine tumors, renal cell carcinoma, hepatocellular carcinoma and pancreatic cancer. In addition, the Company has specialism in neurotoxin research and operates three research and development centers located in France, the United Kingdom and the United States.
- Revenue in EUR (TTM)3.31bn
- Net income in EUR617.10m
- Incorporated1998
- Employees5.33k
- LocationIpsen SA65 Quai Georges GorseBOULOGNE-BILLANCOURT 92100FranceFRA
- Phone+33 158335000
- Fax+33 158335001
- Websitehttps://www.ipsen.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aurobindo Pharma Ltd | 3.21bn | 351.45m | 8.14bn | 15.69k | 23.18 | 2.46 | 15.67 | 2.53 | 54.12 | 54.12 | 494.54 | 509.35 | 0.6827 | 1.38 | 6.25 | -- | 7.46 | 9.24 | 10.35 | 13.43 | 56.54 | 54.15 | 10.93 | 12.72 | 1.18 | 16.12 | 0.1821 | -- | 16.68 | 8.19 | 64.62 | 6.06 | 17.96 | -- |
| Swedish Orphan Biovitrum AB (publ) | 2.04bn | 188.60m | 8.61bn | 1.75k | 44.56 | 2.61 | 17.59 | 4.22 | 6.19 | 6.19 | 69.32 | 105.59 | 0.3603 | 1.50 | 4.72 | 13,058,130.00 | 3.33 | 5.93 | 4.43 | 7.60 | 76.60 | 77.42 | 9.25 | 16.61 | 0.4994 | 3.56 | 0.3487 | 0.00 | 17.74 | 19.34 | -8.68 | -0.0729 | 53.61 | -- |
| CSPC Pharmaceutical Group Ltd | 4.12bn | 770.70m | 8.67bn | 23.50k | 11.21 | -- | 12.47 | 2.10 | 0.5488 | 0.5488 | 2.93 | -- | -- | -- | -- | 1,480,162.00 | -- | 16.08 | -- | 21.57 | 71.51 | 72.95 | 19.25 | 19.63 | -- | -- | -- | 35.51 | 1.66 | 12.16 | -3.58 | 13.77 | -2.58 | 25.33 |
| Lupin Ltd | 2.22bn | 212.05m | 8.88bn | 18.97k | 42.00 | 5.61 | 25.61 | 4.01 | 41.89 | 41.89 | 437.85 | 313.60 | 0.8524 | 1.41 | 4.36 | -- | 8.24 | 1.43 | 13.34 | 2.22 | 66.80 | 59.70 | 9.67 | 2.04 | 0.9991 | 8.64 | 0.1689 | 79.28 | 20.25 | 6.41 | 345.15 | 30.18 | -1.17 | 9.86 |
| Sichuan Biokin Pharmaceutical Co Ltd | 750.86m | 558.83m | 8.95bn | 2.09k | 16.02 | 13.64 | -- | 11.92 | 10.95 | 10.95 | 14.71 | 12.86 | 1.37 | 1.85 | 41.29 | 2,828,652.00 | 102.16 | -- | 138.88 | -- | 95.70 | -- | 74.42 | -- | 3.75 | 828.87 | 0.1314 | -- | -20.11 | -- | -176.40 | -- | -- | -- |
| Kyowa Kirin Co Ltd | 2.61bn | 476.37m | 9.10bn | 5.97k | 19.01 | 1.86 | 15.12 | 3.49 | 154.53 | 154.53 | 845.28 | 1,577.38 | 0.455 | 1.61 | 4.24 | 76,040,840.00 | 8.32 | 6.28 | 9.55 | 7.08 | 74.06 | 75.45 | 18.28 | 14.96 | 3.06 | -- | 0.0272 | 47.25 | 11.01 | 10.25 | 51.55 | 10.52 | 10.28 | 9.86 |
| Catalent Inc | 3.82bn | -1.09bn | 9.46bn | 17.80k | -- | 2.82 | -- | 2.47 | -6.48 | -6.48 | 22.69 | 20.06 | 0.3993 | 4.36 | 2.87 | 232,303.40 | -11.36 | 2.88 | -12.91 | 3.26 | 18.96 | 31.03 | -28.44 | 6.35 | 1.74 | 0.0154 | 0.5797 | 0.00 | -11.22 | 11.59 | -153.00 | -- | 26.69 | -- |
| Ipsen SA | 3.31bn | 617.10m | 9.58bn | 5.33k | 15.46 | 2.47 | 10.00 | 2.90 | 7.39 | 7.72 | 39.66 | 46.25 | 0.554 | 1.99 | 5.23 | 620,920.20 | 10.48 | 9.71 | 13.93 | 13.33 | 82.72 | 82.76 | 18.91 | 16.02 | 0.989 | 30.43 | 0.089 | 19.23 | 4.75 | 7.08 | 4.03 | 9.75 | -8.65 | 3.71 |
| Mankind Pharma Ltd | 1.14bn | 211.88m | 9.64bn | 18.47k | 45.57 | 9.30 | 37.20 | 8.42 | 47.69 | 47.69 | 257.65 | 233.73 | -- | -- | -- | -- | -- | -- | -- | -- | 68.94 | -- | 18.79 | -- | 2.37 | 116.65 | 0.0212 | -- | 18.12 | -- | 49.23 | -- | -- | -- |
| Recordati Industria Chmc Frmctc SpA | 2.14bn | 388.86m | 10.26bn | 4.46k | 27.36 | 5.57 | 18.89 | 4.80 | 1.79 | 1.79 | 9.92 | 8.81 | 0.5177 | 1.67 | 4.53 | 480,087.10 | 9.41 | 11.67 | 12.13 | 15.02 | 67.82 | 70.43 | 18.18 | 21.45 | 0.9518 | 7.55 | 0.4883 | 42.46 | 12.36 | 9.02 | 24.61 | 4.50 | 81.68 | 5.46 |
| Beijing Wantai Biolog Pha Ent Co Ltd | 429.69m | 16.35m | 10.51bn | 3.84k | 697.67 | 6.43 | -- | 24.45 | 0.0933 | 0.0933 | 2.68 | 10.12 | 0.2058 | 0.8371 | 0.8434 | 878,660.70 | 0.7531 | 24.08 | 0.9228 | 31.80 | 76.97 | 85.18 | 3.66 | 34.95 | 3.84 | -- | 0.0258 | 9.88 | -50.73 | 41.18 | -73.65 | 33.61 | 36.35 | -- |
| Shionogi & Co Ltd | 2.50bn | 929.29m | 10.54bn | 4.96k | 11.11 | 1.42 | 10.27 | 4.22 | 557.64 | 557.64 | 1,499.18 | 4,357.54 | 0.3189 | 0.9378 | 3.75 | 87,735,430.00 | 11.77 | 12.57 | 13.40 | 14.24 | 86.76 | 84.43 | 36.91 | 37.91 | 5.37 | -- | 0.0092 | 26.77 | 1.97 | 3.41 | -12.40 | 3.38 | 2.17 | 11.22 |
| Torrent Pharmaceuticals Ltd | 1.19bn | 183.47m | 10.76bn | 14.92k | 58.65 | 14.17 | 39.62 | 9.06 | 48.94 | 48.94 | 316.97 | 202.58 | 0.7135 | 1.19 | 5.66 | 7,192,170.00 | 11.02 | 8.34 | 17.25 | 13.03 | 74.96 | 71.78 | 15.44 | 13.18 | 0.6142 | 7.24 | 0.3697 | 61.65 | 11.51 | 6.93 | 33.02 | 30.58 | -8.17 | 26.93 |
| Eisai Co Ltd | 4.25bn | 243.21m | 10.84bn | 11.07k | 43.10 | 2.09 | 22.72 | 2.55 | 147.86 | 147.86 | 2,586.27 | 3,050.54 | 0.5583 | 0.986 | 4.50 | 67,023,670.00 | 3.30 | 5.29 | 4.36 | 7.16 | 79.06 | 76.91 | 5.90 | 8.68 | 1.80 | -- | 0.1506 | 74.13 | -0.3561 | 2.90 | -23.50 | -7.72 | -2.11 | 1.30 |
Data as of Jul 05 2024. Currency figures normalised to Ipsen SA's reporting currency: Euro EUR
14.56%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Parvus Asset Management Europe Ltd.as of 08 Apr 2024 | 6.63m | 7.91% |
| The Vanguard Group, Inc.as of 06 Jun 2024 | 1.23m | 1.47% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 860.13k | 1.03% |
| Oddo BHF Asset Management SASas of 31 May 2024 | 859.68k | 1.03% |
| BlackRock Fund Advisorsas of 06 Jun 2024 | 783.89k | 0.94% |
| BlackRock Advisors (UK) Ltd.as of 06 Jun 2024 | 536.17k | 0.64% |
| Liontrust Investment Partners LLPas of 30 Apr 2024 | 368.16k | 0.44% |
| Amundi Asset Management SA (Investment Management)as of 05 Jun 2024 | 337.85k | 0.40% |
| Geode Capital Management LLCas of 27 Jun 2024 | 309.05k | 0.37% |
| Dimensional Fund Advisors LPas of 06 Jun 2024 | 298.69k | 0.36% |
More ▼
Data from 31 Dec 2023 - 26 Jun 2024Source: FactSet Research Systems Inc.
